Alembic Pharmaceuticals has received U.S. Food and Drug Administration final approval for its abbreviated new drug application for Carbidopa, Levodopa and Entacapone Tablets in different strengths.
The combination drug is indicated for the treatment of Parkinson’s. The approved ANDA is therapeutically equivalent to reference listed drug Stalevo Tablets of Orion Corporation, Alembic said on Friday announcing the U.S. FDA approval.
The company’s shares closed 1.32% lower at ₹799.05 apiece on the BSE.
Published – February 06, 2026 10:07 pm IST
